1. Expression profile of Bcl‐2 family proteins in newly diagnosed multiple myeloma patients
- Author
-
Cristina De Ramón, Elizabeta A. Rojas, Irena Misiewicz‐Krzeminska, Ignacio J. Cardona‐Benavides, Myriam Cuadrado, Isabel Isidro, María‐José Calasanz, Manuela Fernandez, Ramón García‐Sanz, Noemi Puig, M. Teresa Cedena, Bruno Paiva, Laura Rosiñol, Joaquín Martínez‐López, Joan Bladé, Juan J. Lahuerta, Jesús F. San Miguel, María V. Mateos, Luis A. Corchete, Norma C. Gutiérrez, and GEM/PETHEMA cooperative study group
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Abstract Antiapoptotic Bcl‐2 family proteins are involved in myeloma cell survival. To date, their expression in multiple myeloma (MM) patients has mostly been analyzed at the RNA level. In the present study, we quantified for the first time the protein expression of the Bcl2‐family members using a capillary electrophoresis immunoassay in 120 newly diagnosed MM patients, aged ≤65 years, treated in the context of the PETHEMA/GEM2012 study. We found that the pattern of expression of Bcl‐2 family proteins was highly heterogeneous among patients. Although cases with t(11;14) had significantly higher levels of Bcl‐2/Bcl‐xL and Bcl‐2+Bim+Bax/Bcl‐xL ratios than those without t(11;14), the presence of this translocation was not synonymous with such high levels of expression. Conversely, some patients with other genetic alterations also showed higher levels of those ratios. Survival analysis revealed that the high expression of Bad and Puma proteins was associated with significantly longer overall survival (p = 0.001 and p
- Published
- 2024
- Full Text
- View/download PDF